Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialAndrew X. Zhu, Yvonne H. Sada, Sadahisa Ogasawara et al.|The Lancet Oncology|2018Cited by 2.5k
Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.Omid Hamid, Marc S. Ernstoff, Stephen V. Liu et al.|Journal of Clinical Oncology|2021Cited by 12